ZURICH, Nov 4 (Reuters) - The following are some of the main factors expected to affect Swiss stocks on Wednesday:
Swiss specialty chemicals maker Clariant posted a smaller third-quarter net profit of 25 million Swiss francs, ahead of forecasts even as recession sapped demand for its products.
For related news, click on [CLN.VX]
Swiss dental implant maker Nobel Biocare more than doubled its third-quarter net profit as its cost-cutting efforts offset the continuing drop in demand, but refrained from giving an outlook.
For related news, click on [NOBN.VX]
Swiss drugmaker Novartis AG is buying a 85 percent stake in Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical for some $125 million to boost its presence in the fast growing market.
For related news, click on [NOVN.VX]
UBS AG has taken key roles on two landmark deals to shore up British banks — landing the Swiss bank a welcome boost in fees and prestige on the same day it shocked the market with worse-than-expected results.
For related news, click on [UBSN.VX]
COMPANY STATEMENTS [CNR-CH]
* Private Equity Holding (PEHN.S): Half-year results as of September 30, 2009 [PEHN.S]
* Swisscom SCMN.VXacquires Credit Suisse subsidiary WECO [SCMN.VX]
EQUITY RESEARCH [CH-RCH]
FOR COMPANIES TRADING EX-DIVIDEND, PLEASE CLICK ON:
.EX.S for all Swiss stocks
.EXSMI.S for blue chips
.EXNSMI.S for other stocks